Alchemab Therapeutics Announces Biggest Ever Life Sciences Investment from British Business Bank to Advance its AI-Enabled Clinical Pipeline of Next-Generation Human-Derived Antibodies
Alchemab Therapeutics, pioneering the next generation of antibody therapeutics for hard-to-treat diseases, led by Jane Osbourn, OBE, FMedSci, PhD, and the team, has extended its Series A financing…
Read the full articleYou might also wanna read
Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet
Alchemab Therapeutics, a London-based clinical-stage BioTech startup, has extended its Series A financing with €29.3 million (£25 million/$3
Alchemab Therapeutics extends Series A with £25m investment
Alchemab Therapeutics has extended its Series A financing with £25m from the British Business Bank, marking the Bank’s largest investment in
British Business Bank invests £25m in Alchemab Therapeutics, its largest direct investment in a life sciences company
British Business Bank invests £25m in Alchemab Therapeutics, its largest direct investment in a life sciences company Simon Cottam Thu, 07/0
Proteina Invests 3.4 Billion Won in ABX to Expand AI-Based Antibody Design
Proteina will invest 3.4 billion won in ABX Biosciences and become its largest shareholder to expand AI-based de novo antibody drug design a
British Business Bank’s British Growth Partnership Fund I invests in Draig Therapeutics Series B financing round
British Business Bank’s British Growth Partnership Fund I invests in Draig Therapeutics Series B financing round Adam Bird Tue, 07/14/2026 -
BioNTech’s investment provides a template for UK growth, say ABPI
The innovative biopharmaceutical company BioNTech has announced a major investment of up to £1bn over 10 years in the UK, potentially creati
Comments
Sign in to join the conversation.
No comments yet. Be the first.